# Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer

> **NCT04903652** · PHASE2 · COMPLETED · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (actual)

## Conditions studied

- HER2-positive Advanced Breast Cancer

## Interventions

- **DRUG:** Pyrotinib Maleate
- **DRUG:** Vinorelbine

## Key facts

- **NCT ID:** NCT04903652
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-01
- **Primary completion:** 2022-02-01
- **Final completion:** 2022-02-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04903652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04903652, "Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04903652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*